What is Chemours Co's earnings per share (EPS)?

Chemours Co (CC) reported diluted earnings per share of -$2.57 for fiscal year 2025. This represents a -658.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Chemours Co Financials

Trailing 12 months to June 30, 2026

Revenue $5.8B -0.9% YoY

Net Income -$304.0M +29.0% YoY

EPS (Diluted) -$2.00 +30.1% YoY

Free Cash Flow $218.0M +503.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Chemours Co (CC) reported $5.8B in revenue over the twelve months to Jun 30, 2026, down 0.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CC FY2025 2026-08-29

Margin compression is colliding with a highly leveraged balance sheet, while cash generation remains unusually volatile.

Revenue was essentially flat from FY2024 to FY2025, but gross margin fell from 19.8% to 15.5%, indicating that the earnings deterioration came from weaker economics per dollar sold rather than a major volume decline. With debt-to-equity at 16.4x, that margin pressure has a much larger effect on shareholders because a thin equity base absorbs the operating swings.

The FY2025 return to positive free cash flow did not represent a return to profitability: net income was -$386M while operating cash flow was $264M. Free cash flow of $51M also benefited from capital expenditures falling to $213M from $360M, so cash conversion improved partly through lower reinvestment rather than stronger earnings.

Earnings quality has been inconsistent across periods: FY2024 produced net income of $69M alongside operating cash flow of -$633M, while FY2025 reversed that relationship. Meanwhile, total equity fell to $250M from $571M, making leverage ratios increasingly sensitive to relatively small changes in business results.

Financial Health Signals

Financial Health Score 16/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Chemours Co's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Chemours Co, and counted as zero in the overall score.

Growth

Chemours Co's revenue grew a modest 0.4% year-over-year to $5.8B. This slow but positive growth earns a score of 24/100.

Leverage

Chemours Co has elevated debt relative to equity (D/E of 16.40), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 2/100, reflecting increased financial risk.

Liquidity

Chemours Co's current ratio of 1.78 indicates adequate short-term liquidity, earning a score of 51/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Chemours Co generated $264.0M in operating cash flow, capex of $213.0M consumed most of it, leaving $51.0M in free cash flow. This results in a low score of 21/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Not available for Chemours Co, and counted as zero in the overall score.

Piotroski F-Score Neutral

4/9

Chemours Co passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

Chemours Co reported a net loss of $386.0M while generating $264.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.8B

YoY+0.4%

5Y CAGR+3.2%

10Y CAGR+0.2%

Chemours Co generated $5.8B in revenue in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Net Income

-$386.0M

YoY-659.4%

Chemours Co reported -$386.0M in net income in fiscal year 2025. This represents a decrease of 659.4% from the prior year.

EPS (Diluted)

-$2.57

YoY-658.7%

Chemours Co earned -$2.57 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 658.7% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$51.0M

YoY+105.1%

5Y CAGR-37.6%

Chemours Co generated $51.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 105.1% from the prior year.

Cash & Debt

$670.0M

YoY-6.0%

5Y CAGR-9.5%

10Y CAGR+6.2%

Chemours Co held $670.0M in cash against $4.1B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.51

YoY-48.8%

5Y CAGR-12.5%

10Y CAGR-1.2%

Chemours Co paid $0.51 per share in dividends in fiscal year 2025. This represents a decrease of 48.8% from the prior year.

Shares Outstanding

150M

YoY+0.4%

5Y CAGR-1.9%

10Y CAGR-1.9%

Chemours Co had 150M shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Margins & Returns

Gross Margin

15.5%

YoY-4.2pp

5Y CAGR-5.9pp

10Y CAGR-1.2pp

Chemours Co's gross margin was 15.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.2 percentage points from the prior year.

Net Margin

-6.7%

YoY-7.8pp

5Y CAGR-11.1pp

10Y CAGR-5.1pp

Chemours Co's net profit margin was -6.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.8 percentage points from the prior year.

Return on Equity

-154.4%

YoY-166.5pp

5Y CAGR-181.3pp

10Y CAGR-83.0pp

Chemours Co's ROE was -154.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 166.5 percentage points from the prior year.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$108.0M

YoY-0.9%

5Y CAGR+3.0%

10Y CAGR+1.1%

Chemours Co invested $108.0M in research and development in fiscal year 2025. This represents a decrease of 0.9% from the prior year.

Capital Expenditures

$213.0M

YoY-40.8%

5Y CAGR-4.4%

10Y CAGR-8.5%

Chemours Co invested $213.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 40.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CC quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	$5.8B	$5.8B+0.4%	$5.8B-4.9%	$6.1B-11.0%	$6.8B+7.7%	$6.3B+27.7%	$5.0B-10.1%	$5.5B-16.8%	$6.6B+7.4%	$6.2B+14.5%	$5.4B-5.5%	$5.7B-11.1%	$6.4B-6.2%	$6.9B
Cost of Revenue	$4.9B	$4.9B+5.7%	$4.6B-2.8%	$4.8B-8.4%	$5.2B+5.1%	$5.0B+27.2%	$3.9B-12.6%	$4.5B-4.4%	$4.7B+5.2%	$4.4B+3.3%	$4.3B-9.8%	$4.8B-6.1%	$5.1B-6.0%	$5.4B
Gross Profit	$886.0M	$902.0M-21.0%	$1.1B-12.3%	$1.3B-19.4%	$1.6B+17.0%	$1.4B+29.4%	$1.1B+0.4%	$1.1B-46.1%	$2.0B+13.0%	$1.7B+58.2%	$1.1B+15.5%	$955.0M-29.8%	$1.4B-7.1%	$1.5B
R&D Expenses	N/A	$108.0M-0.9%	$109.0M+0.9%	$108.0M-8.5%	$118.0M+10.3%	$107.0M+15.1%	$93.0M+16.3%	$80.0M-2.4%	$82.0M+1.2%	$81.0M0.0%	$81.0M-16.5%	$97.0M-32.2%	$143.0M-12.8%	$164.0M
SG&A Expenses	N/A	$799.0M+33.6%	$598.0M-53.5%	$1.3B+81.1%	$710.0M+19.9%	$592.0M+12.3%	$527.0M-3.8%	$548.0M-16.6%	$657.0M+5.0%	$626.0M-33.8%	$946.0M+49.7%	$632.0M-7.7%	$685.0M-10.8%	$768.0M
Interest Expense	N/A	$269.0M+2.3%	$263.0M+26.4%	$208.0M+27.6%	$163.0M-11.9%	$185.0M-11.9%	$210.0M+1.0%	$208.0M+6.7%	$195.0M-8.9%	$214.0M-2.3%	$219.0M+65.9%	$132.0M	$0	$0
Income Tax	N/A	$109.0M+194.6%	$37.0M+156.1%	-$66.0M-140.5%	$163.0M+139.7%	$68.0M+270.0%	-$40.0M+44.4%	-$72.0M-145.3%	$159.0M-3.6%	$165.0M+1016.7%	-$18.0M+81.6%	-$98.0M-165.8%	$149.0M-2.0%	$152.0M
Net Income	-$304.0M	-$386.0M-659.4%	$69.0M+127.3%	-$253.0M-143.8%	$578.0M-4.9%	$608.0M+177.6%	$219.0M+521.2%	-$52.0M-105.2%	$995.0M+33.4%	$746.0M+10557.1%	$7.0M+107.8%	-$90.0M-122.5%	$400.0M-5.4%	$423.0M
EPS (Diluted)	-$2.00	-$2.57-658.7%	$0.46+127.1%	-$1.70-146.6%	$3.65+1.4%	$3.60+172.7%	$1.32+512.5%	-$0.32-105.9%	$5.45+39.4%	$3.91+9675.0%	$0.04+108.0%	-$0.50-122.6%	$2.21-5.6%	$2.34

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.6B+15.2%	$1.4B+3.9%	$1.3B-11.1%	$1.5B-7.4%	$1.6B+18.1%	$1.4B+0.7%	$1.4B-9.9%	$1.5B
Cost of Revenue	$1.3B+11.6%	$1.2B-0.4%	$1.2B-7.0%	$1.3B-5.6%	$1.3B+18.1%	$1.1B+3.5%	$1.1B-10.5%	$1.2B
Gross Profit	$286.0M+34.9%	$212.0M+36.8%	$155.0M-33.5%	$233.0M-16.2%	$278.0M+17.8%	$236.0M-10.9%	$265.0M-7.3%	$286.0M
R&D Expenses	$27.0M+3.8%	$26.0M	N/A	$26.0M-7.1%	$28.0M+3.7%	$27.0M	N/A	$29.0M
SG&A Expenses	$469.0M+219.0%	$147.0M	N/A	$122.0M-71.2%	$424.0M+244.7%	$123.0M	N/A	$137.0M
Interest Expense	$68.0M-1.4%	$69.0M	N/A	$68.0M+1.5%	$67.0M+1.5%	$66.0M	N/A	$68.0M
Income Tax	$273.0M+3800.0%	$7.0M	N/A	-$8.0M-106.1%	$131.0M+2520.0%	$5.0M-58.3%	$12.0M	$0
Net Income	-$274.0M-844.8%	-$29.0M+38.3%	-$47.0M-202.2%	$46.0M+112.1%	-$380.0M-7500.0%	-$5.0M+54.5%	-$11.0M+65.6%	-$32.0M
EPS (Diluted)	-$1.81-852.6%	-$0.19+38.7%	-$0.31-200.0%	$0.31+112.3%	-$2.53-8333.3%	-$0.03+62.5%	-$0.08+63.6%	-$0.22

Not reported in any period shown, so not listed: Operating Income.

CC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CC quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$7.4B-1.7%	$7.5B-8.9%	$8.2B+7.9%	$7.6B+1.2%	$7.5B+6.6%	$7.1B-2.4%	$7.3B-1.4%	$7.4B+0.9%	$7.3B+20.3%	$6.1B-3.8%	$6.3B+5.7%	$6.0B	N/A
Current Assets	$3.0B-0.5%	$3.0B-21.5%	$3.8B+19.6%	$3.2B-3.9%	$3.3B+27.0%	$2.6B-5.2%	$2.8B-15.7%	$3.3B-5.7%	$3.5B+36.8%	$2.6B+11.0%	$2.3B+18.5%	$1.9B	N/A
Cash & Equivalents	$670.0M-6.0%	$713.0M-40.7%	$1.2B+9.2%	$1.1B-24.1%	$1.5B+31.3%	$1.1B+17.2%	$943.0M-21.5%	$1.2B-22.8%	$1.6B+72.5%	$902.0M+146.4%	$366.0M	$0	$0
Inventory	$1.6B+7.2%	$1.5B+8.5%	$1.3B-3.9%	$1.4B+27.8%	$1.1B+17.0%	$939.0M-13.0%	$1.1B-5.9%	$1.1B+22.7%	$935.0M+21.9%	$767.0M-21.1%	$972.0M-7.6%	$1.1B	N/A
Accounts Receivable	$562.0M-9.2%	$619.0M+21.6%	$509.0M0.0%	$509.0M-21.0%	$644.0M+43.4%	$449.0M-25.4%	$602.0M-23.8%	$790.0M-6.7%	$847.0M+14.2%	$742.0M-2.0%	$757.0M+1.5%	$746.0M	N/A
Goodwill	$46.0M0.0%	$46.0M-54.9%	$102.0M0.0%	$102.0M0.0%	$102.0M-33.3%	$153.0M0.0%	$153.0M	N/A	$153.0M0.0%	$153.0M-7.8%	$166.0M-16.2%	$198.0M0.0%	$198.0M
Total Liabilities	$7.1B+2.8%	$6.9B-7.7%	$7.5B+15.1%	$6.5B+1.0%	$6.5B+3.2%	$6.3B-4.5%	$6.6B+3.5%	$6.3B-1.3%	$6.4B+7.9%	$6.0B-3.4%	$6.2B+169.8%	$2.3B	N/A
Current Liabilities	$1.7B-7.4%	$1.8B-26.8%	$2.5B+31.5%	$1.9B+1.8%	$1.9B+28.8%	$1.4B-6.4%	$1.5B-9.8%	$1.7B+3.7%	$1.6B-6.9%	$1.8B+20.8%	$1.5B+4.9%	$1.4B	N/A
Long-Term Debt	$4.1B+1.0%	$4.1B+1.8%	$4.0B+11.1%	$3.6B-3.6%	$3.7B-7.0%	$4.0B-0.5%	$4.0B+1.7%	$4.0B-3.4%	$4.1B+16.1%	$3.5B-9.9%	$3.9B	$0	N/A
Total Equity	$250.0M-56.2%	$571.0M-20.8%	$721.0M-34.9%	$1.1B+2.4%	$1.1B+33.0%	$813.0M+18.0%	$689.0M-32.1%	$1.0B+17.9%	$860.0M+760.0%	$100.0M-20.6%	$126.0M-96.6%	$3.7B+14.1%	$3.2B
Retained Earnings	$1.2B-27.6%	$1.7B-5.4%	$1.8B-17.9%	$2.2B+24.3%	$1.7B+34.0%	$1.3B+4.3%	$1.2B-14.8%	$1.5B+153.2%	$579.0M+607.9%	-$114.0M+0.9%	-$115.0M	$0	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.2B-1.6%	$7.3B-1.6%	$7.4B-2.2%	$7.5B+1.1%	$7.5B+1.2%	$7.4B-1.8%	$7.5B+0.7%	$7.5B
Current Assets	$3.1B+5.7%	$2.9B-2.4%	$3.0B-6.4%	$3.2B+3.5%	$3.1B+5.7%	$2.9B-2.8%	$3.0B-1.9%	$3.1B
Cash & Equivalents	$671.0M+19.2%	$563.0M-16.0%	$670.0M+9.3%	$613.0M+22.1%	$502.0M+8.2%	$464.0M-34.9%	$713.0M+19.6%	$596.0M
Inventory	$1.5B-5.5%	$1.5B-2.1%	$1.6B+1.4%	$1.5B-0.7%	$1.6B+0.5%	$1.6B+5.9%	$1.5B+2.0%	$1.4B
Accounts Receivable	$773.0M+19.8%	$645.0M+14.8%	$562.0M-31.2%	$817.0M+0.5%	$813.0M+15.5%	$704.0M+13.7%	$619.0M-25.0%	$825.0M
Goodwill	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M
Total Liabilities	$7.2B+2.1%	$7.1B-1.1%	$7.1B-1.9%	$7.3B+0.5%	$7.2B+6.2%	$6.8B-1.8%	$6.9B+1.8%	$6.8B
Current Liabilities	$1.9B+15.7%	$1.6B-4.6%	$1.7B-9.9%	$1.9B+2.4%	$1.8B+9.5%	$1.7B-8.4%	$1.8B+1.9%	$1.8B
Long-Term Debt	$3.8B-6.4%	$4.1B0.0%	$4.1B-0.1%	$4.1B-0.1%	$4.1B+1.0%	$4.1B+0.2%	$4.1B+1.8%	$4.0B
Total Equity	-$49.0M-122.8%	$215.0M-14.0%	$250.0M-8.8%	$274.0M+20.2%	$228.0M-59.7%	$566.0M-0.9%	$571.0M-11.2%	$643.0M
Retained Earnings	$891.0M-24.4%	$1.2B-3.4%	$1.2B-4.8%	$1.3B+2.6%	$1.2B-23.9%	$1.6B-2.6%	$1.7B-3.7%	$1.7B

CC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CC quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	$397.0M	$264.0M+141.7%	-$633.0M-213.8%	$556.0M-26.4%	$755.0M-7.2%	$814.0M+0.9%	$807.0M+24.2%	$650.0M-43.0%	$1.1B+78.1%	$640.0M+7.7%	$594.0M+226.4%	$182.0M-64.0%	$505.0M-36.7%	$798.0M
Capital Expenditures	$179.0M	$213.0M-40.8%	$360.0M-2.7%	$370.0M+20.5%	$307.0M+10.8%	$277.0M+3.7%	$267.0M-44.5%	$481.0M-3.4%	$498.0M+21.2%	$411.0M+21.6%	$338.0M-34.9%	$519.0M-14.1%	$604.0M+37.9%	$438.0M
Free Cash Flow	$218.0M	$51.0M+105.1%	-$993.0M-633.9%	$186.0M-58.5%	$448.0M-16.6%	$537.0M-0.6%	$540.0M+219.5%	$169.0M-73.7%	$642.0M+180.3%	$229.0M-10.5%	$256.0M+176.0%	-$337.0M-240.4%	-$99.0M-127.5%	$360.0M
Investing Cash Flow	$117.0M	-$206.0M+41.6%	-$353.0M-54.1%	-$229.0M+19.4%	-$284.0M-229.1%	$220.0M+194.0%	-$234.0M+51.6%	-$483.0M+0.8%	-$487.0M-31.6%	-$370.0M-203.6%	$357.0M+171.8%	-$497.0M+11.3%	-$560.0M-32.1%	-$424.0M
Financing Cash Flow	-$350.0M	-$126.0M-250.0%	-$36.0M-120.9%	$172.0M+125.1%	-$686.0M-23.8%	-$554.0M-23.4%	-$449.0M-7.2%	-$419.0M+57.8%	-$993.0M-382.1%	$352.0M+188.9%	-$396.0M-157.6%	$687.0M+1149.1%	$55.0M+114.7%	-$374.0M
Dividends Paid	$54.0M	$78.0M-47.3%	$148.0M-0.7%	$149.0M-3.2%	$154.0M-6.1%	$164.0M0.0%	$164.0M0.0%	$164.0M+10.8%	$148.0M+572.7%	$22.0M0.0%	$22.0M-79.0%	$105.0M	$0	$0
Share Buybacks	N/A	N/A	N/A	$69.0M-86.1%	$495.0M+186.1%	$173.0M	$0-100.0%	$322.0M-50.0%	$644.0M+507.5%	$106.0M	$0	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$158.0M+459.1%	-$44.0M-132.1%	$137.0M-6.2%	$146.0M+57.0%	$93.0M+183.0%	-$112.0M-181.2%	$138.0M-0.7%	$139.0M
Capital Expenditures	$44.0M-10.2%	$49.0M+8.9%	$45.0M+9.8%	$41.0M-4.7%	$43.0M-48.8%	$84.0M-22.9%	$109.0M+43.4%	$76.0M
Free Cash Flow	$114.0M+222.6%	-$93.0M-201.1%	$92.0M-12.4%	$105.0M+110.0%	$50.0M+125.5%	-$196.0M-775.9%	$29.0M-54.0%	$63.0M
Investing Cash Flow	$239.0M+643.2%	-$44.0M-2.3%	-$43.0M-22.9%	-$35.0M+16.7%	-$42.0M+51.2%	-$86.0M+19.6%	-$107.0M-42.7%	-$75.0M
Financing Cash Flow	-$289.0M-1421.1%	-$19.0M+48.6%	-$37.0M-640.0%	-$5.0M+81.5%	-$27.0M+52.6%	-$57.0M-167.1%	$85.0M+414.8%	-$27.0M
Dividends Paid	$13.0M0.0%	$13.0M-13.3%	$15.0M+15.4%	$13.0M0.0%	$13.0M-64.9%	$37.0M+2.8%	$36.0M-5.3%	$38.0M

Not reported in any period shown, so not listed: Share Buybacks.

CC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CC quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Gross Margin	15.5%-4.2pp	19.8%-1.7pp	21.4%-2.2pp	23.7%+1.9pp	21.8%+0.3pp	21.5%+2.2pp	19.2%-10.5pp	29.7%+1.5pp	28.2%+7.8pp	20.4%+3.7pp	16.7%-4.4pp	21.1%-0.2pp	21.3%
Net Margin	-6.7%-7.8pp	1.2%+5.3pp	-4.2%-12.6pp	8.5%-1.1pp	9.6%+5.2pp	4.4%+5.3pp	-0.9%-15.9pp	15.0%+2.9pp	12.1%+11.9pp	0.1%+1.7pp	-1.6%-7.8pp	6.2%+0.1pp	6.2%
Return on Equity	-154.4%-166.5pp	12.1%+47.2pp	-35.1%-87.3pp	52.2%-4.0pp	56.2%+29.3pp	26.9%+34.5pp	-7.5%-105.7pp	98.1%+11.4pp	86.7%+79.7pp	7.0%+78.4pp	-71.4%-82.3pp	10.9%-2.3pp	13.2%
Return on Assets	-5.2%-6.2pp	0.9%+4.0pp	-3.1%-10.6pp	7.6%-0.5pp	8.1%+5.0pp	3.1%+3.8pp	-0.7%-14.2pp	13.5%+3.3pp	10.2%+10.1pp	0.1%+1.6pp	-1.4%-8.1pp	6.7%	N/A
Current Ratio	1.78+0.1x	1.66+0.1x	1.55-0.2x	1.70-0.1x	1.800.0x	1.830.0x	1.80-0.1x	1.93-0.2x	2.12+0.7x	1.44-0.1x	1.57+0.2x	1.39	N/A
Debt-to-Equity	16.40+9.3x	7.11+1.6x	5.53+2.3x	3.24-0.2x	3.44-1.5x	4.93-0.9x	5.84+1.9x	3.90-0.9x	4.76-30.5x	35.29+4.2x	31.07+31.1x	0.00	N/A
FCF Margin	0.9%+18.1pp	-17.2%-20.2pp	3.1%-3.5pp	6.6%-1.9pp	8.5%-2.4pp	10.9%+7.8pp	3.1%-6.6pp	9.7%+6.0pp	3.7%-1.0pp	4.7%+10.6pp	-5.9%-4.3pp	-1.5%-6.8pp	5.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	18.0%+2.6pp	15.3%+3.7pp	11.7%-3.9pp	15.6%-1.6pp	17.2%0.0pp	17.3%-2.3pp	19.5%+0.5pp	19.0%
Net Margin	-17.2%-15.1pp	-2.1%+1.4pp	-3.5%-6.6pp	3.1%+26.6pp	-23.5%-23.2pp	-0.4%+0.4pp	-0.8%+1.3pp	-2.1%
Return on Equity	N/A	-13.5%+5.3pp	-18.8%-35.6pp	16.8%+183.5pp	-166.7%-165.8pp	-0.9%+1.1pp	-1.9%+3.0pp	-5.0%
Return on Assets	-3.8%-3.4pp	-0.4%+0.2pp	-0.6%-1.3pp	0.6%+5.7pp	-5.1%-5.0pp	-0.1%+0.1pp	-0.1%+0.3pp	-0.4%
Current Ratio	1.66-0.2x	1.820.0x	1.78+0.1x	1.710.0x	1.70-0.1x	1.76+0.1x	1.66-0.1x	1.72
Debt-to-Equity	N/A	19.07+2.7x	16.40+1.4x	14.98-3.0x	18.02+10.8x	7.19+0.1x	7.11+0.9x	6.20
FCF Margin	7.2%+13.9pp	-6.7%-13.7pp	6.9%-0.1pp	7.0%+3.9pp	3.1%+17.4pp	-14.3%-16.5pp	2.1%-2.0pp	4.2%

Not reported in any period shown, so not listed: Operating Margin.

Similar Companies

$3.4B

$2.9B

$2.4B

$2.3B

$2.2B

Where Chemours Co Ranks

Frequently Asked Questions

What is Chemours Co's annual revenue?

Chemours Co (CC) reported $5.8B in total revenue for fiscal year 2025. This represents a 0.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Chemours Co's revenue growing?

Chemours Co (CC) revenue grew by 0.4% year-over-year, from $5.8B to $5.8B in fiscal year 2025.

Is Chemours Co profitable?

No, Chemours Co (CC) reported a net income of -$386.0M in fiscal year 2025, with a net profit margin of -6.7%.

How much debt does Chemours Co have?

As of fiscal year 2025, Chemours Co (CC) had $670.0M in cash and equivalents against $4.1B in long-term debt.

What is Chemours Co's gross margin?

Chemours Co (CC) had a gross margin of 15.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Chemours Co's net profit margin?

Chemours Co (CC) had a net profit margin of -6.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Chemours Co pay dividends?

Yes, Chemours Co (CC) paid $0.51 per share in dividends during fiscal year 2025.

What is Chemours Co's return on equity (ROE)?

Chemours Co (CC) has a return on equity of -154.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Chemours Co's free cash flow?

Chemours Co (CC) generated $51.0M in free cash flow during fiscal year 2025. This represents a 105.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Chemours Co's operating cash flow?

Chemours Co (CC) generated $264.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Chemours Co's total assets?

Chemours Co (CC) had $7.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Chemours Co's capital expenditures?

Chemours Co (CC) invested $213.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Chemours Co spend on research and development?

Chemours Co (CC) invested $108.0M in research and development during fiscal year 2025.

How many shares does Chemours Co have outstanding?

Chemours Co (CC) had 150M shares outstanding as of fiscal year 2025.

What is Chemours Co's current ratio?

Chemours Co (CC) had a current ratio of 1.78 as of fiscal year 2025, which is generally considered healthy.

What is Chemours Co's debt-to-equity ratio?

Chemours Co (CC) had a debt-to-equity ratio of 16.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Chemours Co's return on assets (ROA)?

Chemours Co (CC) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Chemours Co's Piotroski F-Score?

Chemours Co (CC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Chemours Co's earnings high quality?

Chemours Co (CC) reported a net loss of $386.0M while generating $264.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Chemours Co?

Chemours Co (CC) scores 16 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.